ANIK vs. OSUR, CERS, UTMD, ATRI, SRDX, PLSE, SKIN, NPCE, TCMD, and BVS
Should you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include OraSure Technologies (OSUR), Cerus (CERS), Utah Medical Products (UTMD), Atrion (ATRI), Surmodics (SRDX), Pulse Biosciences (PLSE), Beauty Health (SKIN), NeuroPace (NPCE), Tactile Systems Technology (TCMD), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
OraSure Technologies received 249 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 69.90% of users gave OraSure Technologies an outperform vote while only 64.30% of users gave Anika Therapeutics an outperform vote.
OraSure Technologies has a net margin of 13.23% compared to Anika Therapeutics' net margin of -49.60%. OraSure Technologies' return on equity of 14.50% beat Anika Therapeutics' return on equity.
Anika Therapeutics currently has a consensus target price of $29.50, indicating a potential upside of 8.22%. OraSure Technologies has a consensus target price of $6.38, indicating a potential upside of 16.33%. Given OraSure Technologies' higher probable upside, analysts plainly believe OraSure Technologies is more favorable than Anika Therapeutics.
In the previous week, Anika Therapeutics had 3 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Anika Therapeutics and 2 mentions for OraSure Technologies. Anika Therapeutics' average media sentiment score of 0.50 beat OraSure Technologies' score of -0.07 indicating that Anika Therapeutics is being referred to more favorably in the media.
91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 5.9% of Anika Therapeutics shares are held by insiders. Comparatively, 3.4% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Anika Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
OraSure Technologies has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
OraSure Technologies beats Anika Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Anika Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anika Therapeutics Competitors List
Related Companies and Tools
